A Review of Paroxetine for the Treatment of Vasomotor Symptoms

Abstract

Background:

Studies in recent years have exposed concerns about the safety of hormone replacement therapy (HRT) in the treatment of vasomotor symptoms (VMS) in menopausal women. Numerous studies have examined the use of antidepressants for relief of VMS. Despite recommendations to deny approval of paroxetine mesylate (Brisdelle™) for the treatment of VMS, the Food and Drug Administration (FDA) recently granted it approval for this indication.

Objective:

To evaluate all published literature examining use of paroxetine salts (mesylate and hydrochloride) in the treatment of menopausal VMS.

Methods:

Both PubMed and International Pharmaceutical Abstracts (IPA) were searched using the keywords hot flashes, vasomotor symptoms, menopause, and paroxetine. In PubMed, MeSH terms were used for paroxetine, menopause, and hot flashes. Searches were limited to humans, English language, and clinical trial design. The references for each study identified in this search process were examined in order to locate any additional relevant articles.

Results:

Compared with placebo, paroxetine salts offer a modest benefit in the treatment of menopausal VMS reducing the frequency and severity of weekly hot flashes.

Conclusion:

Paroxetine (mesylate or hydrochloride) is an effective alternative to HRT for the reduction in VMS in menopausal women. Future head-to-head studies with active medications are needed in order to identify the best algorithm of treatment for this condition.

Keywords

paroxetine hot flashes vasomotor symptoms menopause

Get full access to this article

View all access options for this article.

References

Kalantaridou

Dang

Davis

. Hormone therapy in women. In: Dipiro

Talbert

Yee

., eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011:1417–1436.

National Institutes of Health State-of-the-Science Panel. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142(12):1003–1013.

Fugate

Church

. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother. 2004;38(9):1482–1499.

Hall

Frey

Soares

. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs. 2011;71(3):287–304.

Rossouw

Anderson

Prentice

. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

Rossouw

Manson

Kaunitz

. Lessons learned from the women’s health initiative trials of menopausal hormone therapy. Obstet Gynecol. 2013;121(1):172–176.

Goodman

Cobin

Ginzburg

. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2011;17(suppl 6):1–25.

Schmidt

. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause. 2012;9(3):257–271.

Brisdelle™ [prescribing information]. Noven Therapuetics, LLC., Miami, FL; June 2013. http://www.brisdelle.com/pdf/PI_MedGuide.pdf. Accessed July 18, 2013.

10.

Brisdelle™. Food and Drug Administration (FDA) website. In: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Rockville, MD: FDA. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=204516&TABLE1=OB_Rx. Updated July 24, 2013. Accessed July 23, 2013.

11.

DeBattista

. Antidepressant agents. In: Katzung

Masters

Trevor

, eds. Basic and Clinical Pharmacology. 11th ed. New York, NY: The McGraw-Hill Companies, Inc; 2009:509.

12.

Schatzberg

Cole

DeBattista

. Manual of clinical psychopharmacology. 4th ed.Washington, DC: American Psychiatric Publishing, Inc; 2003:47–67.

13.

Catelli

Bhaskar

Lippman

. Pharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal women. Clin Ther. 2013;35(6):862–869.

14.

Simon

Portman

Kaunitz

. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013 Oct;20(10):1027–1035.

15.

Soares

Joffe

Viguera

. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med. 2008;121(2):159–162.

16.

Stearns

Beebe

Iyengar

. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289(21):2827–2834.

17.

Stearns

Isaacs

Rowland

. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil^®) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11(1):17–22.

18.

Weitzner

Moncello

Jacobsen

. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Sympton Manage. 2002;23(4):337–345.

19.

Stearns

Slack

Greep

. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23(28):6919–6930.

20.

Paroxetine. In: Clinical Pharmacology [internet database]. Tampa, FL: Elsevier & Gold Standard. Available at http://clinicalpharmacology-ip.com.ezproxy.samford.edu. Updated July 01, 2013. Accessed July 15, 2013.

21.

Red Book Online [internet database]. Greenwood Village, Colo: Truven Health Analytics, Inc. Available at http://www.micromedexsolutions.com.ezproxy.samford.edu/micromedex2. Accessed July 23, 2013.

22.

Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmacetics Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-299.pdf_Paroxetine%20Mesylate_BioPharmr.pdf. Accessed January 14, 2014.

23.

Generali

Cada

. Paroxetine: hot flashes. Hosp Pharm. 2004;39(2):130–132, 190.

24.

Stearns

Johnson

Rae

. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758–1764.

25.

Kelly

Juurlink

Gomes

. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693. http://www.bmj.com/content/340/bmj.c693?view=long&pmid=20142325. Accessed July 18, 2013.

26.

Baxter

. Stockley’s Drug Interactions. 9th ed. Chicago, IL: Pharmaceutical Press; 2010.

27.

Abajo

Montero

Rodriquez

Madurga

. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol.2006;98(3):304–310.

28.

Verdel

Souverein

Egberts

. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010;47(3):604–609.

29.

Guidance for Industry—Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Recommendations for Clinical Evaluation. www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf. Accessed November 18, 2013.